Casticine, à partir de Vitex trifolia, > = 98%( HPLC)

Code: b0189-5mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Casticin from Vitex trifolia is used to study its mechanisms of action as an antiiflammatory and anticancer agent via processes such as TRAIL-induced apo...


en savoir plus

Votre prix
$553.90 5MG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Casticin from Vitex trifolia is used to study its mechanisms of action as an antiiflammatory and anticancer agent via processes such as TRAIL-induced apoptosis, cell cycle arrest, ROS generation, and glutathione (GSH) depletion.

Biochem/physiol Actions

Tubulin-binding anticancer flavonoid. Casticin induces apoptosis in cancer cells.

Casticin has anticancer, pro-apoptotic, anti-proliferative, anti-asthmatic, and anti-angiogenic properties. In addition, it exhibits anti-inflammatory behavior by means of its inhibitory effect on lipoxygenases and T- & B-lymphocytes. Due to its oestrogenic activity, it is being used to manage Premenstrual syndrome in women. It is also reported to mitigate rheumatoid arthritis and liver fibrosis manifestations.

General description

Casticin is one of the flavonoids present in the traditional Chinese medicine Inula japonica Thunb. It is a polymethyl compound with three rings, a catechol moiety at ortho position, one double bond, two hydroxyl groups, and four methoxy groups. It has been isolated from the fruits, seeds, and leaves of various Vitex species.

Packaging

25 mg in poly bottle

5 mg in glass insert

assay≥98% (HPLC)
biological sourceVitex trifolia
formpowder
InChI keyPJQLSMYMOKWUJG-UHFFFAOYSA-N
InChI1S/C19H18O8/c1-23-11-6-5-9(7-10(11)20)17-19(26-4)16(22)14-12(27-17)8-13(24-2)18(25-3)15(14)21/h5-8,20-21H,1-4H3
Quality Level100
solubilityethanol: 1 mg/mL, clear, colorless to light yellow
storage temp.2-8°C
Code
Description
Unité de vente
Prix annoncé
Qté
B0189-25MG
Unité:25MG
Prix annoncé: $1,827.00
Source:Prix annoncé
Cas Number479-91-4
Ce produit répond aux critères suivants: